Vanda Pharmaceuticals (NASDAQ:VNDA) Posts Quarterly Earnings Results, Misses Expectations By $0.46 EPS

Posted by Brian Himes on Aug 6th, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.46), FiscalAI reports. Vanda Pharmaceuticals had a negative return on equity of 32.26% and a negative net margin of 109.99%.The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $61.92 million.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

Fanapt continued strong growth: Second-quarter prescriptions rose 31% year over year and net product sales increased 23% to $36.0 million, supported by the bipolar I disorder launch and an expanded sales force.
Multiple pipeline and commercial catalysts are approaching: BYSANTI is expected to launch in the second half of 2026, Quimilza has a December 2026 FDA action date, and late-stage readouts for NEREUS, VQW-765, and HETLIOZ are expected by year-end.
Profitability and cash usage deteriorated: Second-quarter net loss widened to $62.5 million from $27.2 million a year earlier, while operating expenses rose 25% to $114.3 million; management expects 2026 cash burn to exceed 2025 levels.
HETLIOZ sales remain pressured by generic competition: Second-quarter revenue fell 66% to $5.6 million, although approximately $7 million of shipments delayed until July will be recognized in the third quarter.
NEREUS launch results remain difficult to assess: The product generated $1.0 million in recognized sales, while $12.6 million of wholesaler-related revenue was constrained because of uncertainty around patient demand and potential returns from elevated inventory levels.

Vanda Pharmaceuticals Stock Down 4.5%

Vanda Pharmaceuticals stock opened at $5.09 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15. Vanda Pharmaceuticals has a 1-year low of $4.14 and a 1-year high of $9.94. The company has a market cap of $306.06 million, a PE ratio of -1.26 and a beta of 0.64. The stock’s 50 day moving average price is $5.84 and its 200 day moving average price is $6.78.

Analysts Set New Price Targets

Several equities analysts recently issued reports on VNDA shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, June 4th. Finally, Wall Street Zen downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 9th. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $14.30.

Read Our Latest Stock Analysis on VNDA

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its holdings in shares of Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 5,328 shares in the last quarter. Jain Global LLC purchased a new stake in Vanda Pharmaceuticals during the fourth quarter worth about $94,000. Quarry LP acquired a new position in Vanda Pharmaceuticals during the third quarter worth about $53,000. Boothbay Fund Management LLC acquired a new position in Vanda Pharmaceuticals during the third quarter worth about $72,000. Finally, Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals during the second quarter worth about $69,000. 88.14% of the stock is currently owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.